Search results

592 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Medical technologies guidance Remove Medical technologies guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter

Cenobamate for focal onset seizures in epilepsy [ID1553]

In development [GID-TA10661] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]

In development [GID-TA10639] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488

In development [GID-TA10432] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

In development [GID-TA10470] Expected publication date: 27 January 2021

Type

Technology appraisal guidance

Status

In development
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]

In development [GID-TA10626] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]

In development [GID-TA10703] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]

In development [GID-TA10381] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]

In development [GID-TA10482] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]

In development [GID-TA10650] Expected publication date: 25 August 2021

Type

Technology appraisal guidance

Status

In development
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

In development [GID-TA10612] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]

In development [GID-TA10619] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]

In development [GID-TA10624] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
The Assurance Nasal Alar SpO2 Sensor (discontinued)

In development [GID-MT510] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

In development [GID-MT517] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

In development [GID-MT536] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

In development [GID-MT516] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
OraQuick® HCV Rapid Antibody Test (discontinued)

In development [GID-MT117] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

In development [GID-MT130] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

In development [GID-MT163] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Microthane implants for breast reconstruction or breast augmentation (discontinued)

In development [GID-MT267] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SILK artery reconstruction device (discontinued)

In development [GID-MT81] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Workplace health for employees with disabilities and long-term conditions

In development [GID-PHG58] Expected publication date: TBC

Type

NICE guideline

Status

In development
Diagnostic services

In development [GID-CGWAVE0773] Expected publication date: TBC

Type

NICE guideline

Status

In development
Reducing the mortality and morbidity for healthcare associated infections

In development [GID-NG10059] Expected publication date: TBC

Type

NICE guideline

Status

In development
Hernia

In development [GID-CGWAVE0771] Expected publication date: TBC

Type

NICE guideline

Status

In development
Workplace health - older employees

In development [GID-PHG59] Expected publication date: 24 March 2016

Type

NICE guideline

Status

In development
Personal, social, health and economic education focusing on sex and relationships and alcohol education

In development [GID-PHG0] Expected publication date: TBC

Type

NICE guideline

Status

In development
Housing: planning to improve health and wellbeing

In development [GID-NG10053] Expected publication date: TBC

Type

NICE guideline

Status

In development
Assessment, referral and management of Adrenal dysfunction

In development [GID-NG10052] Expected publication date: TBC

Type

NICE guideline

Status

In development
Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

In development [GID-TA10418] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Prostate cancer (prevention) - dutasteride [ID75]

In development [GID-TAG409] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

In development [GID-TAG411] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Obesity - lorcaserin [ID337]

In development [GID-TAG420] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]

In development [GID-TAG369] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455

In development [GID-TA10356] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

In development [GID-TAG393] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Hypercholesterolemia - mipomersen [ID524]

In development [GID-TAG437] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

In development [GID-TAG433] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Thrombophilia [ID393]

In development [GID-TAG374] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Systemic lupus erythematosus - prasterone [ID392]

In development [GID-TAG373] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Falls - faller's clinics [ID103]

In development [GID-TAG375] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]

In development [GID-TAG436] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell) - cetuximab [ID9]

In development [GID-TAG395] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism (prevention) - rivaroxaban [ID463]

In development [GID-TAG427] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development